— Know what they know.
Not Investment Advice

CAI NASDAQ

Caris Life Sciences, Inc.
1W: +5.7% 1M: +1.5% 3M: +108.2% YTD: +20.3% 1Y: +2.5%
$33.67
+1.22 (+3.74%)
After Hours: $33.79 (+0.12, +0.36%)
Weekly Expected Move ±9.6%
$26 $29 $32 $35 $38
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Buy · Power 68 · $9.2B mcap · 11M float · 39.66% daily turnover · Short 53% of daily vol
Credit Risk of going bust: lower than 54% of companies Debt: 4.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.19 (down 99.4%), Caris Life Sciences, Inc. would be worth roughly what it owes.
Total debt $452.4M against a stock market value of $9.17B.
Distance to default 5.52 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $196.7M (short-term plus half of long-term), stock volatility 68.1%; Altman Z'' -0.33. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$1.1B +227.5% ▲
5Y CAGR: -17.3%
Total Liabilities
$548M -80.7% ▼
5Y CAGR: -24.3%
Shareholders Equity
$577M +123.1% ▲
5Y CAGR: -3.6%
Cash & Investments
$800M +1109.5% ▲
5Y CAGR: +76.7%
Total Debt
$379M -10.7% ▼
5Y CAGR: -29.0%
Net Debt
-$419M -216.2% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2022FY2023FY2024FY2025
— Assets —
Cash$54M$107M$56M$64M$798M
Short-Term Investments$79M$302M$65M$2M$2M
Cash & ST Investments$133M$410M$122M$66M$800M
Net Receivables$144M$40M$55M$88M$112M
Inventory$0$47M$49M$40M$0
Other Current Assets-$62M$6M$5M$8M$86M
Total Current Assets$215M$516M$243M$216M$998M
Property, Plant & Equip.$1.8B$138M$148M$103M$63M
Goodwill & Intangibles$0$19M$19M$19M$19M
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$617M$44M$3M$6M$45M
Total Non-Current Assets$2.4B$201M$170M$128M$128M
Total Assets$2.6B$717M$413M$344M$1.1B
— Liabilities —
Accounts Payable$4M$27M$27M$28M$39M
Short-Term Debt$183M$53M$167K$60M$169K
Deferred Revenue$3M$1M$6M$7M$0
Other Current Liabilities$130M$23M$22M$31M$88M
Total Current Liabilities$320M$137M$95M$165M$127M
Long-Term Debt$1.6B$170M$166M$319M$379M
Other Non-Current Liab.$3M$2.1B$2.3B$2.3B$42M
Total Non-Current Liabilities$1.6B$2.3B$2.5B$2.7B$421M
Total Liabilities$1.9B$2.4B$2.6B$2.8B$548M
— Equity —
Common Stock$2K$138K$38K$38K$283K
Retained Earnings$503M-$1.7B-$2.1B-$2.5B-$2.5B
Accumulated OCI-$6M$2M$218K$210K$936K
Total Stockholders Equity$702M-$1.7B-$2.1B-$2.5B$577M
Total Liabilities & Equity$2.6B$717M$413M$344M$1.1B
— Key Metrics —
Total Debt$1.7B$271M$217M$424M$379M
Net Debt$1.7B$164M$161M$360M-$419M
Total Investments$79M$302M$65M$2M$2M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms